$RLFTF Javitt notes that in their trial enrolled t
Post# of 653
The trial’s Data Safety Monitoring Board has reviewed the trial data twice and both times declared it safe to continue. Javitt says, “We expect topline data at the end of the month and that may well trigger regulatory action if we have a positive readout.”
https://www.biospace.com/article/neurorx-on-t...an-javitt/